CTRI/2019/07/020239招募中3 期
An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with HemophiliaA or B, with or without Inhibitory Antibodies to Factor VIII or IX
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •I 01. Participant must be at least 12 years of age inclusive, at the time of signing the informed consent
- •Type of participant and disease characteristics
- •I 02. Participants with severe hemophilia A or B who have completed a Phase 3 fitusiran clinical trial
- •I 03. Male
- •Informed Consent
- •I 04. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. In countries where legal age of majority is above 18 years, a specific ICF must also be signed by the participantâ??s legally authorized representative.
排除标准
- •Medical conditions
- •E 01. Completion of a surgical procedure within 14 days prior to screening, or currently receiving additional factor concentrate or BPA infusion for postoperative hemostasis
- •Prior/concomitant therapy
- •E 02. Current participation in ITI
- •E 03. Current use of factor concentrates or BPAs as regularly administered prophylaxis designed to prevent spontaneous bleeding episodes
- •E 04. Use of compounds other than factor concentrates or BPAs for hemophilia treatment
- •Prior/concurrent clinical study experience
- •E 05. Received an investigational drug or device, other than fitusiran, within 30 days of anticipated IMP administration or 5 half-lives of the IMP, whichever is longer
- •E 06. Current or prior participation in a gene therapy trial
- •Diagnostic assessments
- •E 07. ALT and/or AST >1.5Ã? upper limit of normal reference range (ULN) for patients who are naïve to fitusiran at study start; ALT and/or AST >5Ã? ULN for patients who were in the fitusiran arm in the parent study
- •Other exclusions
- •E 08. Individuals accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalized
- •E 09. Any country-related specific regulation that would prevent the participant from entering the study (country-specific requirements)
- •E 10. Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures
- •E 11. Participants who are dependent on the Sponsor or Investigator (as defined in section 1.61 of the International Council for Harmonisation (ICH)-Good Clinical Practice (GCP) E6)
- •E 12. Participants are employees of the clinical study site or other individuals directly involved in the conduct of the study, or immediate family members of such individuals
- •E 13. Any specific situation during study implementation/course that may rise ethics considerations
- •E 14. Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
研究者
相似试验
已完成
3 期
ong-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IXHemophiliaJPRN-jRCT2080225111Sanofi K.K.244
已完成
3 期
A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients with Cystinosis.Nephropathic cystinosismetabolic disorder in which the transport of cystine out of the lysosomes is abnormal10000546NL-OMON44053Raptor Pharmaceuticals Europe BV5
进行中（未招募）
1 期
A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients with Nephropathic Cystinosis - RP103-04CystinosisMedDRA version: 12.1Level: LLTClassification code 10011777Term: CystinosisEUCTR2010-018365-34-FRRaptor Therapeutics Inc.20
进行中（未招募）
1 期
A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients with Nephropathic CystinosisCystinosisEUCTR2010-018365-34-NLHorizon Pharma USA, Inc.60
招募中
3 期
An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)HAE1000533010002426Hereditary angioedemaNL-OMON53420Ionis Pharmaceuticals, Inc.11